Dopamine agonist therapy and cardiac valve dysfunction.
Sherlock
Mark
M
Department of Endocrinology, Division of Medical Sciences, University of Birmingham, UK.
Steeds
Richard
R
Toogood
Andy A
AA
D018491:Dopamine Agonists / Q000009:adverse effects* / Q000378:metabolism; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D005355:Fibrosis; D006351:Heart Valves / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D010300:Parkinson Disease / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011985:Receptors, Serotonin / Q000378:metabolism
C098814:5HT-dro2B receptor; D018491:Dopamine Agonists; D011985:Receptors, Serotonin